DE4CC0DE-5FC3-4494-BCBF-4D50B00366B5

Johnson & Johnson Quarterly Profit Beats Analysts' Estimates

By Steve Wynne-Jones
Share this article
Johnson & Johnson Quarterly Profit Beats Analysts' Estimates

Johnson & Johnson, the maker of Neutrogena and Clean & Clear, has topped analysts' estimates for quarterly profit and revenue.

Sales across the company's three main units rose, with the pharmaceutical business surging nearly 20%, to $10.35 billion, accounting for almost half of total sales in the second quarter.

The company's shares were volatile in pre-market trading, recovering from an initial drop to trade up 1.4%, at $126.46.

Net earnings rose to $3.95 billion, or $1.45 per share, in the second quarter, from $3.83 billion, or $1.40 per share, a year earlier.

Excluding items, the company reported a profit of $2.10 per share, beating analysts' average estimate of $2.07.

ADVERTISEMENT

Beating Estimates

Total sales rose to $20.83 billion from $18.84 billion a year ago, above analysts' estimates of $20.39 billion.

International revenue for J&J rose 11.8% in the reported quarter, accounting for nearly half of its total sales.

The health-care conglomerate said that it expects full-year sales of $80.5 billion to $81.3 billion, compared with a prior estimate of $81.0 billion to $81.8 billion. The company cited a strengthening dollar for the trim.

Analysts had expected full-year profit of $8.12 per share and sales of $81.47 billion, according to Thomson Reuters I/B/E/S. J&J said that it now expects adjusted earnings of $8.07 to $8.17 per share, compared with an earlier forecast of $8.00 to $8.20 per share.

News by Reuters, edited by ESM. Click subscribe to sign up to ESM: European Supermarket Magazine.

Get the week's top grocery retail news

The most important stories from European grocery retail direct to your inbox every Thursday

Processing your request...

Thanks! please check your email to confirm your subscription.

By signing up you are agreeing to our terms & conditions and privacy policy. You can unsubscribe at any time.